Translate page

05 medwireNews2

April 2016 - We are delighted to announce that from April we will be bringing you a monthly news service covering the latest clinical and scientific advances in CML.

The news service, provided by medwireNews Springer Healthcare’s independent news bureau, will include summaries of key CML publications. The CML stories are based on articles published in international peer-reviewed journals, or conference sessions and written by highly experienced and knowledgeable writers. 

With this independent educational service we continue to expand our online educational platform complementing other services such as the Virtual Education Program or the Case Discussion Forum. Our aim is to grant equal access to CML education in all parts of the world for the purpose of best possible care for all CML patients.

Read the CML stories of the month:

  • Additional chromosomal abnormalities prognostic for CML  
    Additional chromosomal abnormalities (ACAs) can be used to create two prognostic groups of patients with chronic myeloid leukaemia (CML), suggests research published in Blood.                                                                         
    (Source: Blood, March 2016; Advance online publication) 
  • Pre-TKI cytocine profiling predicts CP-CML outcome
    Measuring levels of transforming growth factor (TGF)-α and interleukin (IL)-6 may help identify patients with newly diagnosed chronic phase–chronic myeloid leukaemia (CP–CML) at risk of a poor outcome from tyrosine kinase inhibitor (TKI) therapy, research suggests.
    (Source: Leukemia, March 2016; Advance online publication)
  • Frontline nilotinib supported for newly diagnosed CP-CML
    Long-term results from the ENESTnd trial indicate a favourable risk–benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase–chronic myeloid leukaemia (CP–CML) diagnosis.
    (Source: Leukemia, March 2016; Advance online publication)